this author has yet to write their bio.
meanwhile lets just say that we are proud admin contributed a whooping 433 entries.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the eisai center for genetics guided dementia discovery (g2d2), a new exploratory research facility in cambridge, massachusetts, u.s., held its opening ceremony and has begun full-scale research activities.
july 3, 2019 – eisai china inc. announced that it would again donate 350,000 yuan to china population welfare foundation for the project “public welfare stars invite you to help the elderly with cognitive impairment go home”, which was jointly organized by china population welfare foundation and tencent news.
on june 24, 2019, eisai china inc. was invited to participate in the “health to countryside” activity, which was organized by the education, science, health and sports committee of cppc in qinghai province, and donated drugs worth of about rmb 530,000 yuan to the qinghai red cross society, which will be used in the “health to countryside” activity in qinghai province. eisai china has always been adhering to its hhc (human health care) corporate philosophy, actively participating in charitable activities and bearing its social responsibilities. from 2014 to 2019, we have donated medicines worth of about rmb 3 million yuan through the “health to countryside” campaign.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a joint research group including scientists from eisai and professor yoshito kishi’s group of harvard university has achieved a total synthesis and obtained results of nonclinical studies of the novel compound, e7130, derived from total synthesis of halichondrin. these results have been published in scientific reports, a scientific journal of nature.1 currently a phase i study to investigate e7130 in solid tumor is underway in japan.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the latest data on its antiepileptic drug (aed) perampanel (product name: fycompa®) will be presented at the 33rd international epilepsy congress (iec) to be held from june 22 to 26, 2019 in bangkok, thailand.
eisai co.,ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) today announced that latest information on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (iswrd) will be presented at the 33rd annual meeting of the associated professional sleep societies (sleep 2019), from june 8 to 12 in san antonio, texas, the united states.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate (product name: lenvima®, “lenvatinib”, kinase inhibitor), eribulin mesylate (product name: halaven®, “eribulin”, halichondrin class microtubule dynamics inhibitor), and morab-202 (antibody drug conjugate, adc) will be given at the 55th annual meeting of the american society of clinical oncology (asco), taking place in chicago, the united states, from may 31 to june 4, 2019. the latest information on h3b-6527 (fibroblast growth factor receptor 4 inhibitor) and h3b-6545 (selective estrogen receptor α covalent antagonist), which were discovered by eisai’s u.s. oncology precision medicine-focused research and development subsidiary h3 biomedicine inc., will also be highlighted in presentations at asco.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announces today that its u.s. subsidiary eisai inc. has bought out purdue pharma l.p.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (iswrd) in patients with alzheimer’s disease. eisai group will solely conduct the development and the commercialization of lemborexant globally.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the latest data on its dual orexin receptor antagonist lemborexant and its antiepileptic drug (aed) perampanel (product name: fycompa®) will be presented at the 2019 annual american academy of neurology (aan) meeting to be held from may 4 to 10, 2019 in philadelphia, pennsylvania in the united states.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that in the 8th meeting of the data safety monitoring board (dsmb) for the global phase iii clinical studies (mission ad) on the investigational oral bace (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: e2609) in early alzheimer’s disease (ad), the dsmb reviewed safety data including the potential for decline in cognition, and recommended the continuation of the studies. elenbecestat is being jointly developed by eisai and biogen inc. (headquarters: cambridge, massachusetts, united states).
1066vip威尼斯 copyright(c) 2011 eisai china lnc.all rights reserved.
沪公网安备31010602001439号
021-62881220
本网站使用cookies以使您获得最佳的体验。为了继续浏览本网站，您需同意我们对cookies的使用。想要了解更多有关于cookies的信息，或不希望当您使用网站时出现cookies，请阅读我们的cookies声明！
we may request cookies to be set on your device. we use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
click on the different category headings to find out more. you can also change some of your preferences. note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
these cookies are strictly necessary to provide you with services available through our website and to use some of its features.
because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. you always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. but this will always prompt you to accept/refuse cookies when revisiting our site.
we fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. you are free to opt out any time or opt in for other cookies to get a better experience. if you refuse cookies we will remove all set cookies in our domain.
we provide you with a list of stored cookies on your computer in our domain so you can check what we stored. due to security reasons we are not able to show or modify cookies from other domains. you can check these in your browser security settings.
we also use different external services like google webfonts, google maps, and external video providers. since these providers may collect personal data like your ip address we allow you to block them here. please be aware that this might heavily reduce the functionality and appearance of our site. changes will take effect once you reload the page.
google webfont settings:
google map settings:
google recaptcha settings:
vimeo and youtube video embeds:
you can read about our cookies and privacy settings in detail on our privacy policy page.
privacy policy